COVID-19 Vaccine Safety: From Bench to Bedside
Within a year of the pandemic being announced, several COVID-19 vaccines were approved and administered to populations around the world. There have been various successes and challenges related to the development and deployment of COVID-19 vaccines and there is significant global interest in ensuring they are safe and effective. Healthcare professionals need credible information to build trust with their patients and answer their questions.
Asian Development Bank and BMJ experts discussed COVID-19 vaccine safety in clinical trials, post-authorization safety methods, and risk communication.
This free webinar was part of the BMJ/ADB COVID-19 Information Centre, providing updated clinical decision support from BMJ Best Practice and e-learning resources from BMJ Learning to frontline healthcare professionals.
Speakers
Dr. Patrick L. Osewe, Chief of Health Sector Group, Asian Development Bank
Dr. Stephen Prior, Microbiologist, and President of Therax, Inc., USA
Dr. Daniel Salmon, Director of the Institute for Vaccine Safety, John Hopkins Bloomberg School of Public Health, USA
Dr. Priscilla Rupali, Infectious diseases physician and Professor, Department of Infectious Diseases, Christian Medical College, Vellore, India
Moderator
Dr. Kieran Walsh, Clinical Director, BMJ
Date | Session / Activity | Presentation Material | Speaker(s) |
---|---|---|---|
21 May 2021 | Presentation 1 |
SARS-CoV-2 and COVID-19 Clinical Trials and Vaccine Safety Dr. Stephen Prior shared hisinsight on vaccination, vaccine safety, and efficacy. He also discussed the comparison of vaccine development processesandCOVID... |
Stephen Prior |
21 May 2021 | Presentation 2 |
Post-Authorization Safety Monitoring This presentation gives an overview of Dr. Salmon's presentation on why safety monitoring is important after vaccination. Dr. Salmon also shared insights... |
Daniel Salmon |
21 May 2021 | Presentation 3 |
Risk Communication: COVID-19 Vaccine Dr. Priscilla Rupali, in this presentation, shared insights on risk communications that emerged from the COVID-19 pandemic and how it has impacted the... |
Priscilla Rupali |